Velan Capital Investment Management
Velan Capital Investment Management reported 42 stocks worth $105M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PRAX (21.3%), IMMX (10.8%) and TARA (8.3%). Compared with Q2 2026, the fund opened new positions in EWTX, QTTB and AARD, added to MPLT, EDSA and EVMN, trimmed PRAX, STRO and XNCR and sold out of TENX, RZLT and VRCA.
Latest filing: what Velan Capital Investment Management did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() PRAX Praxis Precision Medicines I | $22.3M | 21.3% | 77K | −12K (−14%) | 8 of 8 | |
| 2 | ![]() IMMX Immix Biopharma Inc | $11.3M | 10.8% | 1.1M | No change | 6 of 8 | |
| 3 | ![]() TARA Protara Therapeutics Inc | $8.7M | 8.3% | 2.8M | No change | 8 of 8 | |
| 4 | ![]() STRO Sutro Biopharma Inc | $8.2M | 7.8% | 510K | −2,122 (−0%) | 4 of 8 | |
| 5 | ![]() ABVX Abivax SA | $6.5M | 6.2% | 66K | No change | 5 of 8 | |
| 6 | ![]() MPLT Maplight Therapeutics Inc | $6.4M | 6.1% | 625K | +132K (+27%) | 4 of 8 | |
| 7 | ![]() AVR Anteris Technologies Global | $5.4M | 5.2% | 700K | No change | 3 of 8 | |
| 8 | ![]() EDSA Edesa Biotech Inc | $5.4M | 5.2% | 1.3M | +455K (+55%) | 7 of 8 | |
| 9 | ![]() AVTX Avalo Therapeutics Inc | $5M | 4.8% | 324K | No change | 8 of 8 | |
| 10 | ![]() XNCR Xencor Inc | $4.4M | 4.2% | 175K | −80K (−31%) | 3 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
![]() TENX Tenax Therapeutics Inc | $8M | 550K |
![]() RZLT Rezolute Inc | $3.9M | 750K |
![]() VRCA Verrica Pharmaceuticals Inc | $2.9M | 472K |
![]() ADMA Adma Biologics Inc | $2.1M | 250K |
![]() PROF Profound Medical Corp | $1.1M | 170K |
🔒 Free account: see all 14.
Options
valued at the underlying shares| Stock | Type | Value | Shares | Change |
|---|---|---|---|---|
![]() TENX Tenax Therapeutics Inc | Call | $130K | 69K | 0 |
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Velan Capital Investment Management 13F FAQ
What does Velan Capital Investment Management own?
Velan Capital Investment Management reported 42 stocks worth $105M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are PRAX (21.3%), IMMX (10.8%) and TARA (8.3%). The table above lists every position in the filing (the top 10 without an account).
What did Velan Capital Investment Management buy and sell in Q3 2026?
Compared with Q2 2026: 6 new positions, 5 added to, 5 trimmed and 14 sold out. New positions include EWTX, QTTB and AARD. It sold all of TENX, RZLT and VRCA.
When will Velan Capital Investment Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Velan Capital Investment Management's portfolio worth?
The Q3 2026 filing reports $105M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.
























